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ABSTRACT 
Diacerein is generally used in the treatment of Osteoarthritis , this drug comes under the class anthraquinone. The drug is practically 
insoluble in water and exhibits exceptionally slow and intrinsic dissolution rate with poor bioavailability. In the present study, 
diacerein and β-cyclodextrin (β-CD) solid dispersions were prepared with a view to study the effect and influence of β-CD on the 
solubility and dissolution rate of this poorly aqueous soluble drug. Phase solubility profile revealed that the solubility of diacerein 
was significantly increased in the presence of β-CD and indicating the possible 1:1 stoichiometric inclusion complex with a stability 
constant of 339.66 M-1. Effect of variable such as drug: Carrier ratios were studied. Physical characterization of the solid dispersion 
was characterized by Fourier transform infrared spectroscopy (FT-IR), Differential scanning calorimetry (DSC) and X-ray 
diffraction studies (XRD). These studies revealed that a distinct loss of drug crystallinity in the solid dispersion is ostensibly 
accounting for enhancement of dissolution rate in distilled water containing 0.1% Tween 80. The scanning electron microscopy 
(SEM) study revealed that all the binary systems appeared as agglomerates and exhibiting the presence of a homogenous solid phase 
which could also be responsible for the enhanced dissolution rate in comparison with the pure drug. The drug release from the 
prepared solid dispersion exhibited a first order kinetics. Solid dispersion of diacerein showed a 7.66 times fold increase in 
dissolution rate over the pure drug. 
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INTRODUCTION 
Poor aqueous soluble drugs are generally associated 
with certain problems such as slow drug absorption 
which eventually leading to insufficient and variable 
bioavailability
1,2
. Slowly soluble drugs may not only be 
absorbed at a slow rate, they may be incompletely 
absorbed or in some cases largely unabsorbed following 
oral administration due to the limitation of its 
gastrointestinal residence time. Thus, poorly soluble 
drugs or poorly formulated drug products may result in 
incomplete absorption. Approximately 40% of the 
newly discovered drugs are reported to be poorly water 
soluble
3,4
. In an economic point of view, low oral 
bioavailability results in wastage of large portion of 
drug and in turn ultimately adds to cost of drug therapy, 
especially when the drug is expensive one
5
. Therefore, 
certain attempts have been made to enhance the drug 
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solubility of these therapeutic agents to correlate well 
with enhancement of their bioavailability
6, 7, and 8. 
Many 
techniques have been investigated by researchers to 
improve the solubility of poorly aqueous soluble drugs, 
among them solid dispersion technology was proven to 
be a successful technique, and most widely used
 9,10,11, 
12,13
. Numerous insoluble drugs have shown to improve 
their dissolution character upon conversion to solid 
dispersion
14
.
 
Solid dispersion technology is a well 
known process used to increase the dissolution kinetics 
and in turn alters the oral absorption of poorly water 
soluble drugs using water soluble inert carriers
15, 16
. 
Various hydrophilic carriers such as sugars, acids, 
Polyvinyl Pyrrolidone, polyethylene glycol (PEG 4000, 
6000), methyl cellulose, and cyclodextrin have been 
extensively investigated for their improvement of 
dissolution characteristics and bioavailability of poorly 
aqueous soluble drugs. Cyclodextrin are cyclic 
oligosaccharides consist of (ά-1, 4) - linked ά-D 
glucopyranose units and contain a somewhat small 
lipophilic central cavity and a hydrophilic outer surface, 
that results in enhanced solubility and bioavailability of 
such compounds. Cyclodextrin molecules are relatively 
large with a number of hydrogen donors and acceptors 
and, thus in general, they do not permeate lipophilic 
membranes. In the pharmaceutical industry, 
Cyclodextrin have mainly been used as complexing 
agents to increase aqueous solubility of poorly soluble 
drugs and to increase their bioavailability and stability. 
Cyclodextrin have been used to reduce or prevent 
gastrointestinal or ocular irritation, reduce or eliminate 
unpleasant smells or tastes, prevent drug-drug or drug 
additive interactions, or even to convert oils and liquid 
drugs into microcrystalline or amorphous powder. 
Diacerein is chemically 4, 5 diacetyloxy-9, 10 dioxo 
anthracene-2-carboxylic acid, slow acting medicine of 
the class anthraquinone used to treat joint diseases such 
as osteoarthritis (swelling and pain in the joints).it works 
by blocking the action of interlukin-1 beta, a protein 
involved in the inflammation and destruction of 
cartilage that play a role in the development of 
symptoms of degenerative joint diseases such 
osteoarthritis. The major drawback of this drug is its 
poor aqueous solubility (BCS-II classification) 
(0.01mg/ml) and its oral bioavailability is 40-50%.It is 
therefore worthwhile to make a solid dispersion for 
diacerein to improve its solubility. Hence, in this present 
investigation, an attempt was made for diacerein by 
molecular inclusion complexation β-cyclodextrin with 
an aim to improve its pharmaceutical properties such as 
aqueous solubility, dissolution properties with a view of 
increasing its bioavailability and therapeutic efficacy. 
The characterization of the drug, β-CD and complex was 
done by using differential scanning calorimetry (DSC), 
Fourier transform infrared spectroscopy FTIR and 
powder x-ray diffractometry (PX-RD). In vitro aqueous 
solubility and dissolution rate profiles of the complex 
were performed. 
MATERIALS AND METHODS 
 Diacerein and beta-cyclodextrin was obtained as a gift 
sample from Guru of cure pharmaceutical, Pondicherry. 
All other reagents used in the study were of analytical 
grade. 
Preparation of Diacerein β-cyclodextrin solid 
dispersion by kneading method 
A physical mixture of Diacerein and β-cyclodextrin 
(1:1,1:2,1:3,1:4,1:5,1:6,1:7,1:8,1:9 and 1:10 mol/mol) 
was triturated in a mortar with a small volume of 
methanol: water[1:1 vol/vol] solution. The slurry was 
kneaded for 45 min and dried at 45˚c.The dried mass 
was pulverized and sieved through 60 and fraction was 
collected. The prepared powder stored in deccicator for 
further studies. The prepared solid dispersions were 
evaluated for their physicochemical parameters such as 
yield, angle of repose
17
 Carr’s index 18 moisture uptake, 
drug content and in vitro dissolution studies. 
Solid State Studies 
Percent Yield 
The percentage yield of the solid dispersion was 
calculated on the basis of dry weight and carrier with 
respect to the final weight of the inclusion complexes
19
 
% Yield  =  Final weight of the product × 100           [1]      
              Dry weight of the drug and carrier 
Average Particle Size 
The solid dispersion of diacerein were dispersed in 
liquid paraffin and mounted on slides. A random of 200 
particles were measured using a calibrated stage 
micrometer and eye piece micrometer, their average 
particle size were calculated
19
. 
Moisture uptake studies 
The moisture uptake/hygroscopicity of the diacerein 
solid dispersion were assessed by spreading a known 
mass of the sample (5g) evenly over a clean petriplate 
having an internal diameter of 10cm at room 
temperature (20-25˚c).The weight of the sample was 
observed at 0.25, 0.5, 1, 2, 3, 5, 6 hrs. The experiment 
was carried out in triplicate and the moisture uptake in 
percentage was calculated using the formula, 
Moisture uptake (%) = Final weight -Initial weight × 100  
                    Initial weight 
Fourier transforms infrared (FTIR) spectroscopy
19
 
FTIR spectral matching approach was employed to 
detect any possible chemical reaction between drug and 
polymer. Potassium bromide was used to prepare pellets 
for all compounds. The pellet was scanned using FTIR-
5300 spectrometer (shimadzu, Tokyo, Japan).The 
scanning range was 4000-400cm
-1
.  
Differential scanning calorimetry
19
 
DSC analysis was performed for drug and drug in solid 
dispersions using DSC Q200, TA instruments, Mumbai, 
India. The samples (10 mg of diacerein or its equivalent) 
were heated in a sealed aluminum pans at a rate of 5 C 
per/min in a temperature range of 10 - 300 C under 
nitrogen flow of 40 mL/min. An empty aluminum pan 
was used as reference. 
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Scanning electron microscopy
19
 
The surface morphology of drug and binary systems was 
determined using a scanning electron microscopy. Pure 
drug (Diacerein) was mounted on a double faced 
adhesive tape and sputtered with thin gold-palladium 
layer using sputter coater unit and surface topography 
was analyzed with a scanning electron 
microscope(JEOL 457V,Japan) 
X-ray powder diffractometry (XRD) 
Powder X-ray diffraction (PXRD) patterns were 
recorded on a Jeol JDX 8030 X-ray diffractometry 
(Tokyo, Japan) using Ni filtered Cu,K (ά) radiation, a 
voltage of kV,a current of 30mA and receiving slit of 
0.2 in. The samples were analyzed over 2ϴ range of 2-
40˚c with scan step size of 0.0170 (2ϴ) and scan step 
time of 1s. 
Liquid State Studies 
Phase solubility study 
Accurately weighed each sample (25mg) of Diacerein 
was transferred to 25ml conical flask containing various 
concentration of β-cyclodextrin (1, 2, 3, 4, and 5×10-
4
mM).The flasks were closed with corks and shaken at 
room temperature up to 72 hrs using rotator shaker. The 
solutions were filtered through Whatmann no.1 filter 
paper. The filtrates were diluted suitably with double 
distilled water and assayed for diacerein at 255nm 
against double distilled water as blank. The apparent 
stability was calculated using the formula; 
                        Ka= slope/S0 (1-slope) 
Estimation of drug content
19
 
The content of Diacerein in the formulated solid 
dispersion was determined by UV spectrophotometer 
(shimadzu, Japan). An accurately weighed quantity of 
solid dispersion (10 mg) was dissolved in 0.8ml of 
methanol and volume was made up to 10ml with double 
distilled water and the absorbance was measured at 
285nm against blank. The drug content was estimated 
using the formula: 
Drug content (mg/ml) = (Absorbance×slope+intercept) 
× bath volume/1000 
Dissolution rate studies
19
 
The dissolution studies was carried out using USP 
(XXII) apparatus (Electro lab, Mumbai, India) following 
paddle method, freshly prepared double distilled water 
(900ml) was placed in the dissolution flask and allow to 
attain a temperature of 37±0.5˚c. The solid dispersion 
containing a quantity equivalent to 100mg of diacerein 
was filled in hard gelatin capsule (size 2) and placed in 
the basket and immersed in the dissolution medium. The 
basket was rotated at 50rpm for 1hr.Five millilitre of the 
sample was withdrawn at different time intervals of 
0,15,30,45 and 60 min. After each withdrawal, the 
medium was replaced with equal amount of fresh buffer 
to maintain the sink conditions. The drug content was 
estimated by measuring the absorbance at 255nm 
against blank.  
RESULTS AND DISCUSSION 
Compatibility study 
Compatibility studies of diacerein with selected carrier 
β-cyclodextrin were done by FTIR spectral matching 
approach. It was easily understood that there was no 
appearance and disappearance of peaks. The functional 
group (c=o) at 1627cm
-1
 {Thiazeto (3, 2-a) quinolone -
4one}, C=O at 1813 {1, 3-dioxol-2-one} are not 
involved in the reaction. Table1. Shows the appearance 
of band at 1709cm
-1
 (COOH) also exhibited the non 
reactivity of both the compounds .The phase solubility 
diagram for the complex formation between diacerein 
and β-cyclodextrin are presented in Fig.1.The plot 
showed that the aqueous solubility of the diacerein 
increases linearity as a function of β-cyclodextrin 
concentration. The drug apparent stability constant for 
the drug was found to be 339.66M
-1
. The FTIR spectrum 
of Diacerine, β-cyclodextrin,  diacerein with β-
cyclodextrin are shown in Fig.2A,2B and 2C. 
Table 1: Phase solubility studies for Diacerein 
Concentration of β-
Cyclodextrin (10
-4
 mM) 
Absorbance 
0 0.258 
1 0.372 
2 0.392 
3 0.404 
4 0.408 
5 0.430 
 
.  
Figure 1: Phase solubility studies for Diacerein 
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Figure 2A: FTIR spectra of Diacerein     
                                 
 
Figure 2B: FTIR spectra of   β-cyclodextrin 
 
 
Figure 2C: FTIR spectra of diacerein with β-cyclodextrin 
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Preparation and evaluation of solid dispersion 
Ten batches of solid dispersion were prepared using 
diacerein as drug, β-cyclodextrin as carrier by kneading 
method. The prepared solid dispersions was evaluated 
for average particle size, angle of repose, bulk density, 
moisture uptake, drug content and in vitro dissolution 
studies. The angle of repose values was ranged from 22 
- 27˚ for kneading mixture. The formulations have 
shown good flow property. The bulk density value was 
ranged from 0.80 - 0.88g/cc for kneading mixture. The 
compressibility values were ranged from 16 -19% for 
kneading mixture, which was found to be ideal for the 
formulation of tablets. The moisture uptake values were 
6 - 7% for kneading mixture which indicates that the 
powder was hygroscopic in nature. Table2. Shows the 
drug content was ranged 96 - 98% for kneading method. 
Differential scanning calorimetry study 
The DSC studies showed one endothermic peak at 
254.97˚c and one exothermic peak at 128.95˚c, which is 
corresponding to its melting point 250-260˚c. This 
revealed there was no major shifting of peak in the 
chemical complex. The thermogram was shown in Fig. 
3A, 3B and 3C. 
Table 2: Evaluation of solid dispersion of Diacerein 
 
Properties 
Kneading Method 
1:2 1:4 1:6 1:8 1:10 
Percentage Yield 
(%) 
98 97 98 97 96 
Angle of Repose(
0
) 21 22 22 23 21 
Bulk Density(g/cc) 0.82 0.86 0.88 0.84 0.81 
Compressibility (%) 17 16 18 19 19 
Moisture Uptake (%) 6 7 6 6 6 
Drug Content (%) 98 97 98 96 97 
 
 
    Figure 3A: DSC Thermogram of Diacerein 
                             
Figure 3B: DSC thermogram of β-cyclodextrin 
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                          Figure 3C: DSC thermogram of diacerein with β-cyclodextrin 
 
X-RD study 
The X-RD spectra of pure diacerein ,β-cyclodextrin (β-
CD),and diacerein with β-CD was shown in Fig. 4A,4B 
and 4C.The diffraction spectrum of solid dispersion vis-
a-vis pure drug carrier and mixture indicates the changes 
produced drug crystal structure as seen from the figure it 
can be clearly noted that the X-RD pattern of diacerein + 
β-cyclodextrin become very broaden due to lower 
crystallinity nature observed at 2ϴ (5,10,17,25,27) there 
are overall amorphous with poor crystalline structure 
present in the mixture. 
 
 
Figure 4A: XRD of diacerein 
 
Figure 4B: XRD of β-cyclodextrin 
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Figure 4C: XRD of diacerein with β-cyclodextrin 
 
In-vitro dissolution studies 
The in vitro dissolution studies were carried out using 
USP (XXII) dissolution apparatus following paddle 
method for pure drug and solid dispersions using double 
distilled water maintained at 37±1˚c.The samples was 
withdrawn at 15, 30, 45 and 60 min. Fig5. Shows the 
release of drug from the solid dispersion prepared by 
kneading method, the release of drug from the solid 
dispersions was 30.14(1:2), 40.47(1:4), 82.17(1:6), 
90.13(1:8) at the end of 60 min, where as it was 
observed that batch and 98.22(1:10) within 30min .The 
t50 values of this batch was 30min. Table 3 showed a 
pure drug release of 20.12% at the end of 60 min. The 
solid dispersions improved the dissolution rate to 
7.66times fold as to pure drug. 
 
 
Figure 5: In vitro release profile of pure drug and solid dispersion of diacerein for Pure drug and mixture (1:2, 1:4, 1:6, 
1:8 and 1:10) 
Table 3: in vitro dissolutions profile of diacerine solid dispersion 
Time (min) Cumulative % of drug dissolved 
Pure drug Drug to carrier ratio 
1:2 1:4 1:6 1:8 1:10 
0 0 0 0 0 0 0 
15 4.33 10.17 14.19 18.38 25.14 60.12 
30 12.82 16.22 20.17 36.01 40.26 98.22 
45 16.17 25.47 28.65 51.89 67.18 - 
60 20.12 30.14 40.47 82.17 90.13 - 
                               
Scanning electron microscopy study 
SEM image of diacerein shows crystalline nature, the 
SEM images for the binary mixture depicted that the 
mixture exhibits more agglomerates as compared to the 
crystalline nature of diacerein, which accounts for the 
increased solubility of diacerein (Fig.6A, 6B and 6C).
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IN VITRO RELEASE PROFILE OF PURE DRUG AND SOLID DISPERSION OF DIACERINE 
 
PURE DRUG 
DRUG TO CARRIER RATIO 1:2 
DRUG TO CARRIER RATIO 1:4 
DRUG TO CARRIER RATIO 1:6 
DRUG TO CARRIER RATIO 1:8 
DRUG TO CARRIER RATIO 1:10 
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Figure 6A: SEM image of diacerein 
 
 
Figure 6B: SEM image of β-cyclodextrin 
 
 
                                      Figure 6C: SEM of diacerein with β-cyclodextrin 
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CONCLUSION 
The objective of the present study was to prepare solid 
dispersion of diacerein using β-cyclodextrin. Diacerein 
was selected as drug due to its poor aqueous solubility 
and β-cyclodextrin used as a carrier. The compatibility 
studies were also conducted by FTIR method showed 
that the drug and carrier was found to be compatible and 
there is no interaction between drug and carrier. The 
solid dispersion prepared using kneading method was 
evaluated for average particle size, angle of repose, bulk 
density, compressibility, and moisture content, drug 
content and in vitro studies. From the above studies it 
was concluded that the batch prepared using 1:10 drug 
polymer ratio by kneading method showed satisfactory 
in vitro dissolution studies. From the DSC studies it can 
be concluded that, the chemical complexation was found 
between drug and carrier. This might be the reason for 
improving the solubility of drug. The X-RD studies 
revealed that overall amorphous form with poor 
crystalline structure present in the mixture which 
ensures conversion of crystalline to amorphous form. 
Hence, it can be concluded that solid dispersion 
complex of drug was giving better dissolution profile as 
compared to pure drug. This in turn, can reduce the dose 
of diacerein, reduce adverse effect and improve 
bioavailability. 
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